Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05613140 · ClinicalTrials.gov registry record
Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 9,230
- Enrollment target
NCT05613140 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 9,230 participants.
The verdict
NCT05613140 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 9,230 participants
- Enrollment target
Study Summary
This study evaluated changes in healthcare resource utilization (HCRU) and costs of care within 12 months following initiation of sacubitril/valsartan (sac/val) in commercially insured and Medicare Advantage (MA) lives in the U.S among adult patients with heart failure with reduced ejection fraction (HFrEF) (cohort 1) and adult patients with chronic heart failure (CHF) (cohort 2).
Interventions
- DRUG sacubitril/valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,230 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2021-11-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05613140
The ClinicalTrials.gov registry entry for NCT05613140 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9,230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sacubitril/valsartan is the first listed.
NCT05613140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05613140 about?
NCT05613140 is a clinical study titled "Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure". This study evaluated changes in healthcare resource utilization (HCRU) and costs of care within 12 months following initiation of sacubitril/valsartan (sac/val) in commercially insured and Medicare Advantage (MA) lives in the U.S among adult patients with heart failure with reduced ejection fraction...
What is the current status of trial NCT05613140?
This trial is currently completed. The enrollment target is 9,230 participants. The study started on 2021-08-02. Estimated completion is 2021-11-05.
What interventions are being tested in trial NCT05613140?
The interventions under investigation include: sacubitril/valsartan (DRUG).
Who is sponsoring clinical trial NCT05613140?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.